Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-22.51%
1 Month
-
3 Months
-
6 Months
-
1 Year
-
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EMBCV---
AAPL138.932.21001.62
GOOG2 181.62-5.8300-0.27
MSFT259.582.75001.07
XOM87.551.91002.23
WFC39.920.75001.91
JNJ179.522.01001.13
FB196.640.99000.51
GE63.54-0.1300-0.20
JPM114.051.44001.28
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume0
Shares Outstanding0
Shares Float0
Trades Count0
Dollar Volume0
Avg. Volume0
Avg. Weekly Volume0
Avg. Monthly Volume0
Avg. Quarterly Volume0

Embecta Corp. (NASDAQ: EMBCV) stock closed at per share at the end of the most recent trading day (a % change compared to the prior day closing price) with a volume of 0.0000 shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 2029 people. Embecta Corp. CEO is .

The one-year performance of Embecta Corp. stock is %, while year-to-date (YTD) performance is %. EMBCV stock has a five-year performance of %. Its 52-week range is between and , which gives EMBCV stock a 52-week price range ratio of %

Embecta Corp. currently has a PE ratio of 6.00, a price-to-book (PB) ratio of 4.45, a price-to-sale (PS) ratio of 2.12, a price to cashflow ratio of 5.40, a PEG ratio of 2.32, a ROA of 55.21%, a ROC of 74.21% and a ROE of 74.21%. The company’s profit margin is 34.94%, its EBITDA margin is 41.40%, and its revenue ttm is $1.17 Billion , which makes it $20.51 revenue per share.

Of the last four earnings reports from Embecta Corp., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Embecta Corp.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Embecta Corp. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Embecta Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Embecta Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Embecta Corp. has a Neutral technical analysis rating based on Technical Indicators (), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Embecta Corp. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Embecta Corp.

Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

CEO:

Telephone: +1 201 847-6880

Address: 1 Becton Drive, Franklin Lakes 07417-1880, NJ, US

Number of employees: 2 029

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits